In the second bit of bad news for Dr. Reddy's Laboratories ($RDY) in days, the company said on Tuesday that a U.S. federal court had temporarily barred sales of its generic of AstraZeneca's ($AZN) blockbuster heartburn drug Nexium in the U.S., Reuters reports. The order came after the U.K. drugmaker objected to the Indian company's product using the purple color that has come to distinguish AstraZeneca's branded drug. Dr. Reddy's launched its generic Nexium in September after weeks of delay because it had to move production to a different plant after the FDA uncovered GMP issues at the facility where it would be made. The Indian drugmaker said on Friday that the FDA had sent it a warning letter for three of its plants. Story | More